Form 8-K
8-K — NRC HEALTH
Accession: 0001437749-26-024663
Filed: 2026-07-28
Period: 2026-07-28
CIK: 0000070487
SIC: 8731 (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — nrc20260724_8k.htm (Primary)
EX-99.1 — EXHIBIT 99.1 (ex_992998.htm)
GRAPHIC (nrchlogo.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — FORM 8-K
8-K (Primary)
Filename: nrc20260724_8k.htm · Sequence: 1
nrc20260724_8k.htm
false
0000070487
0000070487
2026-07-28
2026-07-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 28, 2026
NRC Health
(Exact name of registrant as specified in its charter)
Delaware
001-35929
47-0634000
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
1245 Q Street, Lincoln, Nebraska
68508
(Address of principal executive offices)
(Zip Code)
(402) 475-2525
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
$.001 Par Value Common Stock
NRC
The NASDAQ Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On July 28, 2026, NRC Health, a Delaware corporation (the "Company"), issued a press release announcing its financial and operating results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated by reference herein.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
EXHIBIT
NUMBER
EXHIBIT DESCRIPTION
99.1
NRC Health press release announcing its financial and operating results for the second quarter ended June 30, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
The information contained in Items 2.02 and 9.01 of this report and the exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
The information in Items 2.02 and 9.01 of this report and the exhibits hereto may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements are made based on the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results or events may differ from those anticipated by forward-looking statements. Please refer to the paragraph at the end of the attached press release and various disclosures by the Company in its press releases, stockholder reports, and filings with the Securities and Exchange Commission for information concerning risks, uncertainties, and other factors that may affect future results.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NRC HEALTH
(Registrant)
Date: July 28, 2026
By:
/s/ Shane Harrison
Shane Harrison
Executive Vice President and Chief Financial Officer
EX-99.1 — EXHIBIT 99.1
EX-99.1
Filename: ex_992998.htm · Sequence: 2
ex_992998.htm
Exhibit 99.1
1245 Q Street, Lincoln, NE 68508
P: 1 800 388 4264 | F: 402 475 9061
nrchealth.com
NRC HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS
Second quarter TRCV* increased 11% year-over-year to $151.9 million
LINCOLN, Nebraska, July 28, 2026 — NRC Health (NASDAQ: NRC), a leader in healthcare experience improvement solutions, today announced results for the second quarter 2026.
"Our second quarter was a success on many fronts, including double-digit TRCV growth over the prior year, strong go-to-market and solutions delivery execution, continued commercialization of our product innovations, and the strongest bookings performance for The Governance Institute in seven years, positioning us well for a strong second half of 2026,” said Trent Green, CEO of NRC Health. “As healthcare organizations increasingly seek partners who can help improve experience outcomes, strengthen governance, and build enduring brand value, we believe NRC Health is uniquely differentiated through our three connected strengths: delivering continuous consumer and patient insights, providing trusted partnership and strategic engagement with healthcare leaders, and enabling actions that lead to improved outcomes.”
Second Quarter 2026 Highlights
●
TRCV: Total Recurring Contract Value (TRCV)* was $151.9 million, up 11% year-over-year
●
Revenue: Total revenue was $35.4 million for the three months ended June 30, 2026, up 4% from the prior year
●
Net Income/Loss: GAAP net loss was ($3.3) million, representing (9%) of revenue, and Adjusted Net Income* was $6.9 million, representing 19% of revenue, with the adjustment primarily reflecting previously announced accelerated vesting of stock and associated cash bonuses (“Adjustment Items”)
●
Earnings/Loss Per Share: GAAP net loss per fully diluted share was ($0.15) on 22.0 million fully diluted shares; Adjusted net income per diluted share* was $0.31 on 22.0 million fully diluted shares
●
Adjusted EBITDA: Adjusted EBITDA* was $9.4 million, representing 27% of revenue
●
Cash Flow: Net cash flow from operating activities was $1.4 million, representing 4% of revenue; Free cash flow* was $0.1 million, in each case reflecting cash payment of approximately $2.9 million related to and included in the Adjustment Items
* These financial measures are defined below under the headings “Non-GAAP Financial Measures” and “Total Recurring Contract Value.” Reconciliations of the non-GAAP measures to their most closely comparable GAAP measures are included in the tables in this release.
Dividend Declaration
The Company’s Board of Directors on July 15, 2026, declared a quarterly cash dividend of $0.16 per share. The dividend will be payable on Friday, October 9, 2026, to shareholders of record as of the close of business on Friday, September 25, 2026.
© NRC Health
NRC Health Announces First Quarter 2026 Results
Page 2
July 28, 2026
Earnings Call Information
The company will be hosting a conference call to discuss the financial results on Tuesday, July 28, 2026, at 4:30 p.m. ET. A live webcast and replay of the call will be available on the NRC Health Investor Relations website at nrchealth.com/investor-relations.
About NRC Health
For more than 45 years, NRC Health (NASDAQ: NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health’s commitment to Human Understanding® helps leading healthcare systems get to know the patients, families, consumers, employees, and communities they serve on a human level. Guided by its uniquely empathic heritage, human-centered approach, unmatched national market research, and emphasis on consumer preferences, NRC Health is transforming the healthcare experience, creating strong outcomes across the healthcare journey. For more information, email info@nrchealth.com, or visit www.nrchealth.com.
Total Recurring Contract Value
Total Recurring Contract Value, or TRCV, is viewed by management as a leading indicator of our future revenue trends. It represents the total annualized contract value under customer contracts that are in effect or contractually committed as of the most recent quarter-end, based on contractual pricing and term provisions, and expected to be in force over the subsequent 12 months. TRCV is an operating metric and is not a measure of revenue recognized under U.S. GAAP.
Non-GAAP Financial Measures
In addition to consolidated GAAP financial measures, NRC Health reviews various non-GAAP financial measures that management believes to be important in the evaluation of its operating results and performance, including “Adjusted Net Income,” “Adjusted Earnings per Share,” “Adjusted EBITDA,” “Adjusted EBITDA Margin,” “Free Cash Flow,” and “Free Cash Flow Margin.” Reconciliations of GAAP to non-GAAP financial information are provided later in this release.
NRC Health believes Adjusted Net Income, Adjusted Earnings per Share, Adjusted EBITDA, and Adjusted EBITDA Margin are helpful supplemental measures to assist management and investors in evaluating the Company’s operating results as (i) they exclude certain items that are unusual in nature or whose fluctuation from period to period do not necessarily correspond to changes in the operations of NRC Health’s business, and (ii) the exclusion of non-cash stock compensation is useful for investors applying certain valuation metrics and is consistent with the leverage ratio for our credit facility.
Adjusted Net Income represents net income adjusted to add back management transition costs and non-cash stock compensation and the related tax. The income tax effect on non-GAAP adjustments is calculated by applying the Company's blended federal and state statutory rate to the deductible portion of each adjustment; amounts nondeductible under Section 162(m) of the Internal Revenue Code receive no tax effect. Adjusted EBITDA represents net income before interest, taxes, depreciation, amortization, management transition costs, and non-cash stock compensation items. Adjusted EBITDA Margin represents Adjusted EBITDA divided by our revenue.
© NRC Health
NRC Health Announces First Quarter 2026 Results
Page 3
July 28, 2026
Management transition costs, presented in the Company's prior earnings releases as "non-recurring executive compensation," consist of costs related to the Company's executive leadership transition. The caption was revised in the current period to more accurately reflect the composition of these costs. For the three and six months ended June 30, 2025, these costs consisted of bonuses tied to compensation arrangements for our new CEO and existing executive leaders. For the three and six months ended June 30, 2026, these costs consist of bonuses paid to certain executives to cover anticipated tax obligations in connection with amendments to their 2025 equity awards, as previously disclosed, and approximately $270,000 of severance costs incurred in connection with team restructurings implemented by newly appointed executives.
NRC Health considers Free Cash Flow to be a measure that provides useful information to management and investors about our liquidity. Free Cash Flow does not represent residual cash flow available for discretionary expenditures. We define Free Cash Flow as net cash provided by operating activities less capital expenditures. Free Cash Flow Margin represents Free Cash Flow divided by our revenue.
There is no comprehensive, authoritative guidance for the presentation of such non-GAAP information, which is only meant to supplement GAAP results by providing additional information that management utilizes to assess performance.
Forward-Looking Statements
This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by their use of terms or phrases such as “believes,” “expect,” “focus,” “potential,” “will,” derivations thereof, and similar terms and phrases. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements, including those risks and uncertainties as set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2025, and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.
Media Contact
marketing@nrchealth.com
Investor Contact
ir@nrchealth.com
© NRC Health
NRC Health Announces First Quarter 2026 Results
Page 4
July 28, 2026
NRC HEALTH
Condensed Consolidated Statements of Income
(In thousands except per share data, unaudited)
Three months ended
June 30,
Six months ended
June 30,
2026
2025
2026
2025
Revenue
$
35,392
$
34,038
$
70,195
$
67,588
Operating expenses:
Direct
13,564
12,974
27,210
26,031
Selling, general, and administrative
22,945
17,734
36,364
28,089
Depreciation and amortization
2,121
1,742
4,290
3,284
Total operating expenses
38,630
32,450
67,864
57,404
Operating income (loss)
(3,238
)
1,588
2,331
10,184
Other income (expense):
Interest income
20
21
55
41
Interest expense
(1,321
)
(1,032
)
(2,576
)
(1,932
)
Other, net
2
4
32
11
)
Total other expense
(1,299
)
(1,007
)
(2,489
)
(1,880
)
Income (loss) before income taxes
(4,537
)
581
(158
)
8,304
Provision for income taxes
(1,254
)
687
(97
)
2,623
Net income (loss)
$
(3,283
)
$
(106
)
$
(61
)
$
5,681
Earnings (loss) per share of common stock:
Basic
$
(0.15
)
$
(0.01
)
$
(0.01
)
$
0.25
Diluted
$
(0.15
)
$
(0.01
)
$
(0.01
)
$
0.25
Weighted average shares and share equivalents outstanding:
Basic
22,009
22,658
21,905
22,814
Diluted
22,009
22,658
21,905
22,820
© NRC Health
NRC Health Announces First Quarter 2026 Results
Page 5
July 28, 2026
NRC HEALTH
Condensed Consolidated Balance Sheets
(Dollars in thousands except share amounts and par value)
June 30,
2026
December 31,
2025
(unaudited)
Assets
Current assets:
Cash and cash equivalents
$
3,327
$
4,139
Accounts receivable, net
9,324
11,108
Other current assets
10,155
4,962
Total current assets
22,806
20,209
Property and equipment, net
39,497
40,474
Goodwill
66,152
66,152
Other, net
7,697
8,043
Total assets
$
136,152
$
134,878
Liabilities and Shareholders’ Equity
Current liabilities:
Current portion of notes payable, net of unamortized debt issuance costs
$
4,016
$
4,014
Accounts payable and accrued expenses
4,990
4,066
Accrued wages and bonuses
5,355
7,218
Deferred revenue
16,716
16,201
Dividends payable
3,542
3,625
Other current liabilities
400
1,496
Total current liabilities
35,019
36,620
Notes payable, net of current portion and unamortized debt issuance costs
86,012
75,021
Other non-current liabilities
8,572
9,247
Total liabilities
129,603
120,888
Shareholders’ equity:
Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued
-
-
Common stock, $0.001 par value; authorized 110,000,000 shares, issued 31,975,649 in 2026 and 31,966,504 in 2025, outstanding 22,139,315 in 2026 and 22,637,252 in 2025
32
32
Additional paid-in capital
192,998
183,880
Retained earnings (accumulated deficit)
(24,507
)
(17,298
)
Treasury stock
(161,974
)
(152,624
)
Total shareholders’ equity
$
6,549
$
13,990
Total liabilities and shareholders’ equity
$
136,152
$
134,878
© NRC Health
NRC Health Announces First Quarter 2026 Results
Page 6
July 28, 2026
NRC HEALTH
Condensed Consolidated Statements of Cash Flows
(In thousands, unaudited)
Three months ended
June 30,
Six months ended
June 30,
2026
2025
2026
2025
Cash flows from operating activities:
Net income
$
(3,283
)
$
(106
)
$
(61
)
$
5,681
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
2,121
1,742
4,290
3,284
Deferred income tax expense (benefit)
-
(1,892
)
(36
)
(32
)
Reserve for uncertain tax positions
52
73
(4
)
149
Non-cash share-based compensation expense
7,371
307
8,979
478
Change in fair value of contingent consideration
-
51
-
82
Loss on extinguishment of debt
-
-
-
67
Amortization of debt issuance costs
27
32
54
47
Net changes in assets and liabilities:
Trade accounts receivable
1,509
(1,090
)
1,784
(1,362
)
Prepaid expenses and other current and long-term assets
330
(395
)
(1,297
)
(2,814
)
Deferred contract costs, net
192
(35
)
(433
)
(11
)
Operating lease assets and liabilities, net
(1
)
(27
)
(31
)
(53
)
Accounts payable
(719
)
(470
)
223
157
Accrued expenses, wages, and bonuses
(120
)
1,140
(1,009
)
668
Income taxes receivable and payable
(5,612
)
(571
)
(4,347
)
(651
)
Deferred revenue
(481
)
102
454
(183
)
Net cash provided by (used in) operating activities
1,386
(1,139
)
8,566
5,507
Cash flows from investing activities:
Capital expenditures
(1,324
)
(3,010
)
(3,158
)
(5,996
)
Net cash used in investing activities
(1,324
)
(3,010
)
(3,158
)
(5,996
)
Cash flows from financing activities:
Borrowings on notes payable
-
19,943
-
47,681
Payments on notes payable
(1,031
)
(722
)
(2,061
)
(29,446
)
Borrowings on revolving loan
19,500
20,000
22,000
28,000
Payments on revolving loan
(6,500
)
(23,500
)
(9,000
)
(28,003
)
Payment of debt issuance costs
-
(73
)
-
(135
)
Payments on finance lease obligations
(2
)
(3
)
(5
)
(5
)
Proceeds from the exercise of share-based awards
-
-
139
132
Payment of acquisition contingent consideration
-
-
(484
)
(280
)
Repurchase of shares for treasury
(7,643
)
(5,990
)
(9,578
)
(10,910
)
Payment of dividends on common stock
(3,606
)
(2,734
)
(7,231
)
(5,504
)
Net cash provided by (used in) financing activities
718
6,921
(6,220
)
1,530
Change in cash and cash equivalents
780
2,772
(812
)
1,041
Cash and cash equivalents at beginning of period
2,547
2,502
4,139
4,233
Cash and cash equivalents at end of period
$
3,327
$
5,274
$
3,327
$
5,274
© NRC Health
NRC Health Announces First Quarter 2026 Results
Page 7
July 28, 2026
NRC HEALTH
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands, except per share data, unaudited)
Adjusted Net Income and Adjusted Earnings per Share
Three months ended
June 30,
Six months ended
June 30,
2026
2025
2026
2025
Net income (loss)
$
(3,283
)
$
(106
)
$
(61
)
$
5,681
Add back:
Management transition costs1
3,160
6,640
3,160
6,640
Tax on management transition costs
2
(180
)
(468
)
(180
)
(468
)
Non-cash stock compensation
7,371
307
8,979
478
Tax on non-cash stock compensation
2
(210
)
22
(470
)
(21
)
Adjusted net income
$
6,858
$
6,395
$
11,428
$
12,310
Earnings (loss) per share of common stock, diluted
$
(0.15
)
$
(0.01
)
$
(0.01
)
$
0.25
Weighted average shares and share equivalents outstanding, diluted
22,009
22,658
21,905
22,820
Adjusted earnings per share of common stock, diluted
$
0.31
$
0.28
$
0.52
$
0.54
Adjusted weighted average shares and share equivalents outstanding, diluted
22,113
22,661
22,049
22,820
1)
See 'Non-GAAP Financial Measures' above for a description of the composition of management transition costs and the change from prior period presentation.
2)
The income tax effect on management transition costs and non-cash stock compensation reflects only the tax deductible portion of these add-backs; compensation subject to the deduction limitation under Section 162(m) of the Internal Revenue Code receives no offsetting tax benefit. Because the current period reflects a pre-tax loss rather than pre-tax income, the income tax provision does not fully reflect the impact of the non-deductibility that would be captured in a profitable period, which has the effect of increasing Adjusted Net Income for the period.
© NRC Health
NRC Health Announces First Quarter 2026 Results
Page 8
July 28, 2026
Adjusted EBITDA and Adjusted EBITDA Margin
Three months ended
June 30,
Six months ended
June 30,
2026
2025
2026
2025
Net income (loss)
$
(3,283
)
$
(106
)
$
(61
)
$
5,681
Add back:
Depreciation and amortization
2,121
1,742
4,290
3,284
Interest expense
1,321
1,032
2,576
1,931
Income taxes
(1,254
)
687
(97
)
2,623
Management transition costs1
3,160
6,640
3,160
6,640
Non-cash stock compensation
7,371
307
8,979
478
Adjusted EBITDA
$
9,436
$
10,302
$
18,847
$
20,637
Net income (loss) margin
(9
)%
-
%
-
%
8
%
Adjusted EBITDA margin
27
%
30
%
27
%
31
%
1)
See 'Non-GAAP Financial Measures' above for a description of the composition of management transition costs and the change from prior period presentation.
Free Cash Flow and Free Cash Flow Margin
Three months ended
June 30,
Six months ended
June 30,
2026
2025
2026
2025
Net cash provided by (used in) operating activities
$
1,386
$
(1,139
)
$
8,566
$
5,507
Less:
Capital expenditures
1,324
3,010
3,158
5,996
Free cash flow
$
62
$
(4,149
)
$
5,408
$
(489
)
Net cash provided by operating activities margin
4
%
(3
)%
12
%
8
%
Free cash flow margin
-
%
(12
)%
8
%
(1
)%
© NRC Health
GRAPHIC
GRAPHIC
Filename: nrchlogo.jpg · Sequence: 7
Binary file (7911 bytes)
Download nrchlogo.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 9
v3.26.1
Document And Entity Information
Jul. 28, 2026
Document Information [Line Items]
Entity, Registrant Name
NRC Health
Document, Type
8-K
Document, Period End Date
Jul. 28, 2026
Entity, Incorporation, State or Country Code
DE
Entity, File Number
001-35929
Entity, Tax Identification Number
47-0634000
Entity, Address, Address Line One
1245 Q Street
Entity, Address, City or Town
Lincoln
Entity, Address, State or Province
NE
Entity, Address, Postal Zip Code
68508
City Area Code
402
Local Phone Number
475-2525
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock
Trading Symbol
NRC
Security Exchange Name
NASDAQ
Entity, Emerging Growth Company
false
Amendment Flag
false
Entity, Central Index Key
0000070487
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details
Name:
dei_DocumentInformationLineItems
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration